Tardive Dyskinesia - Causes, Symptoms, and Treatments

Tardive dyskinesia (TD) is a movement disorder that can develop after months or years of taking certain medications and, for some, may continue even after stopping them.

It involves involuntary, repetitive movements—often of the face, lips, tongue, or limbs—that can affect confidence, social connections, and everyday tasks. This guide covers what causes TD, which drugs are associated with it, how to recognize symptoms early, and proven treatments. It’s educational only and not a substitute for medical advice—always consult your prescriber before changing any medication.

What is tardive dyskinesia?

TD is most often linked to long-term exposure to dopamine receptor–blocking agents (DRBAs), especially antipsychotics and some gastrointestinal medicines. Typical features include lip smacking, chewing motions, tongue protrusion, grimacing, blinking, and choreiform movements of the arms and legs. For a deeper overview, see resources from NINDS and a clinical review on StatPearls.

Risk rises with total exposure time and higher doses. Although many newer “atypical” antipsychotics have a lower average risk than older “typical” agents, no drug in this class is completely risk-free. Early recognition and action improve outcomes; for evidence-based recommendations, browse a guideline summary on PubMed.

Medications linked to TD

Several medicines can increase the risk of tardive dyskinesia, especially with long-term or high-dose use. Five examples to know:

Five medicines commonly associated with TD

1. Haloperidol (Haldol) — a first-generation antipsychotic with a well-documented TD risk; see safety details via MedlinePlus.
2. Fluphenazine — another first-generation antipsychotic; TD risk increases with dose and duration. Learn more at MedlinePlus.
3. Risperidone (Risperdal) — an atypical antipsychotic with lower average risk than older agents, but TD can still occur; see the medication guide on MedlinePlus.
4. Olanzapine (Zyprexa) — an atypical antipsychotic with reported TD cases, especially with prolonged exposure; details at MedlinePlus.
5. Metoclopramide (Reglan) — an anti-nausea/GERD medicine with an FDA boxed warning for TD; long-term use is discouraged. See the FDA’s safety communication here and the consumer overview on MedlinePlus.

Other dopamine-blocking agents—including prochlorperazine (anti-nausea) and various long-acting injectable antipsychotics—can also cause TD. If you’re unsure about your personal risk, ask your clinician to review your full medication list, including “as needed” and over-the-counter products; see background information on prochlorperazine and a literature overview of long-acting injectables on PubMed.

Who is at higher risk?

• Longer duration and higher doses of antipsychotics or other DRBAs
• Older age (risk increases notably over ~55)
• Female sex
• Diabetes, prediabetes, or metabolic syndrome
• Mood disorders or a history of substance use
• Past extrapyramidal symptoms (e.g., parkinsonism, akathisia) with antipsychotic initiation
• Coexisting neurologic conditions or prior brain injury

Recognizing signs and symptoms

TD symptoms are involuntary, usually repetitive, and often fluctuate—worsening with stress or excitement and improving during sleep. Watch for:

• Face and mouth: lip smacking, puckering, chewing motions, grimacing
• Tongue: darting, writhing, or protruding movements
• Eyes: rapid blinking or eyelid spasms
• Limbs: jerking, writhing, or piano-playing finger movements
• Trunk/neck: rocking, swaying, shoulder shrugging, pelvic thrusting
• Speech/swallowing: slurred speech, trouble articulating, drooling, or dysphagia

Clinicians commonly use the Abnormal Involuntary Movement Scale (AIMS) to screen for and track severity; you can view a copy of the tool here (PDF). If you or a loved one notices new movements, record short videos and contact your clinician rather than waiting for the next routine visit.

How TD is diagnosed and monitored

TD is diagnosed clinically: providers consider a history of DRBA exposure, the appearance and timing of characteristic movements, and rule out other conditions that could explain symptoms. They’ll also look for medication interactions and confirm the timeline (weeks to years of exposure before onset).

Regular monitoring helps catch TD early. Many clinics screen at baseline and then every 3–6 months for patients taking antipsychotics or metoclopramide. Ask how often you should be assessed and whether interim check-ins (e.g., video visits) are available if symptoms change; for practical monitoring advice, see searches on PubMed.

Treatment options that work

1) Talk with your prescriber before making any changes

Do not stop medications on your own. For many, antipsychotics are essential for stability and safety. If TD appears, your clinician may consider dose reduction, a slower titration, or carefully discontinuing the offending drug when feasible—balancing relapse risk against TD control.

2) Consider switching strategies

When appropriate, switching to an antipsychotic with a lower TD liability can be considered. Clozapine has comparatively low TD risk and may be an option for selected patients; review its benefits and safety on MedlinePlus. Any change should be individualized based on diagnosis, prior response, and side-effect tolerance.

3) VMAT2 inhibitors: first-line pharmacologic treatments

Valbenazine and deutetrabenazine are FDA-approved to treat TD. They inhibit vesicular monoamine transporter 2 (VMAT2), which can reduce excessive dopamine signaling and involuntary movements. See medication information for valbenazine and deutetrabenazine, and review practice guidance via PubMed.

• Valbenazine: typically once-daily dosing; common side effects include sleepiness and dry mouth.
• Deutetrabenazine: often twice-daily dosing; monitor for somnolence and mood changes.

Improvements may appear within weeks and persist with continued therapy. Your prescriber will check for drug interactions (e.g., CYP2D6 inhibitors), coexisting mental health needs, and insurance coverage when choosing and dosing a VMAT2 inhibitor.

4) Other therapies sometimes used

• Botulinum toxin injections for focal, function-limiting movements (e.g., jaw or eyelids).
• Physical, occupational, and speech therapy to improve gait, posture, articulation, and swallowing.
• Address modifiable contributors: manage blood sugar, optimize sleep, reduce excessive caffeine, and review interacting drugs.
• Use caution with anticholinergics (e.g., benztropine); they may worsen TD even if they help other movement side effects.

5) Practical self-management tips

• Keep a symptom diary or brief phone videos to document changes between visits.
• Ask about AIMS screening frequency and your personal risk factors.
• Maintain consistent sleep, hydration, and nutrition; limit stimulants if they exacerbate movements.
• Seek education and community through advocacy groups like NAMI.

When to seek urgent care

• New or rapidly worsening movements that impair breathing, swallowing, or walking
• Severe neck or jaw spasms, high fever, confusion, or pronounced muscle rigidity
• Thoughts of self-harm or harm to others

These may signal conditions other than TD (e.g., acute dystonia or neuroleptic malignant syndrome) or complications that require immediate medical attention.

Prevention and medication safety

• Use the lowest effective dose of DRBAs and reassess the need regularly.
• For metoclopramide, avoid treatment beyond ~12 weeks when possible due to TD risk—see the FDA warning here.
• Discuss alternatives for chronic nausea, migraine, or GI symptoms that don’t rely on dopamine blockade.
• Manage metabolic risks (e.g., diabetes); for general guidance, visit the CDC.
• Minimize unnecessary polypharmacy and schedule routine AIMS screenings; report new movements promptly.

Key takeaways

• Tardive dyskinesia is most often linked to dopamine-blocking medicines used for psychiatric and gastrointestinal conditions.
• Five examples to know: haloperidol, fluphenazine, risperidone, olanzapine, and metoclopramide.
• Don’t stop medicines suddenly—work with your prescriber on dose adjustments, switching strategies, and VMAT2 inhibitors when appropriate.
• Early detection matters. Regular AIMS screening and self-monitoring can reduce disability and improve quality of life.
• With careful medication management, evidence-based treatment, and ongoing follow-up, many people can significantly reduce TD symptoms.